GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (FRA:6A3A) » Definitions » Net Margin %

Autolus Therapeutics (FRA:6A3A) Net Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Autolus Therapeutics's Net Income for the three months ended in Sep. 2024 was €-73.97 Mil. Autolus Therapeutics's Revenue for the three months ended in Sep. 2024 was €0.00 Mil. Therefore, Autolus Therapeutics's net margin for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for Autolus Therapeutics's Net Margin % or its related term are showing as below:

FRA:6A3A' s Net Margin % Range Over the Past 10 Years
Min: -58716.53   Med: -4258.91   Max: -1035.48
Current: -2677.9


FRA:6A3A's Net Margin % is ranked worse than
83.02% of 1013 companies
in the Biotechnology industry
Industry Median: -140.3 vs FRA:6A3A: -2677.90

Autolus Therapeutics Net Margin % Historical Data

The historical data trend for Autolus Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autolus Therapeutics Net Margin % Chart

Autolus Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial -4,259.23 -58,693.97 -9,426.91 -2,403.01 -12,272.77

Autolus Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11,305.53 - -522.13 - -

Competitive Comparison of Autolus Therapeutics's Net Margin %

For the Biotechnology subindustry, Autolus Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Autolus Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Autolus Therapeutics's Net Margin % falls into.



Autolus Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Autolus Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-191.087/1.557
=-12,272.77 %

Autolus Therapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-73.967/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Autolus Therapeutics  (FRA:6A3A) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Autolus Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Autolus Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Autolus Therapeutics Business Description

Traded in Other Exchanges
Address
191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics Headlines

No Headlines